Commentary: Aducanumab: Appropriate Use Recommendations
J Prev Alzheimers Dis
.
2021;8(4):412-413.
doi: 10.14283/jpad.2021.45.
Authors
P Scheltens
1
,
E G B Vijverberg
Affiliation
1
Philip Scheltens, MD,PhD, Alzheimercentrum Amsterdam, Amsterdam UMC, Locatie VUmc, De Boelelaan 1117/1118, 1081 HZ Amsterdam, T: +31 (0)20 4440816, p.scheltens@amsterdamumc.nl.
PMID:
34585214
DOI:
10.14283/jpad.2021.45
No abstract available
MeSH terms
Amyloid / drug effects*
Antibodies, Monoclonal, Humanized / therapeutic use*
Guidelines as Topic / standards*
Humans
Substances
Amyloid
Antibodies, Monoclonal, Humanized
aducanumab